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850 The Journal of Thoracic and CardioObjectives: p38 mitogen-activated protein kinase is associated with many clinical
entities characterized by inflammation. We postulated that inhibition of p38 mito-
gen-activated protein kinase with FR167653 attenuates inflammation and the de-
velopment of pulmonary hypertension in monocrotaline-treated rats.
Methods: Rats were divided into 4 groups: (1) the control group (daily 0.9% saline),
(2) the FR group (daily FR167653, 2 mg · kg1 · d1), (3) the MCT group (daily
0.9% saline the day after a single monocrotaline dose, 60 mg/kg), and (4) the
MCTFR group (daily FR167653, 2 mg · kg1 · d1, the day after a single MCT
dose). Body weight, pulmonary artery pressure, and morphometric changes of the
pulmonary artery with the histopathologic method were observed weekly for 4
weeks. Also, p38 mitogen-activated protein kinase activity and inflammatory cyto-
kine expression in the lung were measured.
Results: Four weeks after monocrotaline administration, mean pulmonary artery
pressure in the MCTFR group was lower than in the MCT group (MCTFR vs
MCT: 24.7  1.9 vs 36.5  2.1 mm Hg; P  .05). In morphometric analysis the
percentage of medial wall thickness and the percentage of muscularization in the
MCTFR group were reduced compared with those in the MCT group after 4
weeks (P  .05); however, the number of macrophages was not significantly
different. p38 mitogen-activated protein kinase activity was significantly attenuated
in the MCTFR group compared with in the MCT group (7.2 0.52 vs 2.1 0.23
fold-increase, P  .05, at 1 week). Although mRNA levels of tumor necrosis factor
 and interleukin 1 were reduced in the MCTFR group compared with in the
MCT group (tumor necrosis factor : 1.18  0.36 vs 3.05  1.12 fold-increase, P
 .05, at 2 weeks; interleukin 1: 2.2  0.34 vs 4.4  1.09 fold-increase, P  .05,
at 1 week), FR167653 did not suppress increased monocyte chemotactic protein 1
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extracellular stimuli. MAPK activity r
Lu et al Cardiopulmonary Support and PhysiologymRNA expression induced by monocrotaline (3.2  0.62 vs 3.1  0.42 fold-
increase, at 1 week).
Conclusion: FR167653 significantly attenuates the expression of inflammatory
cytokines, ultimately preventing the progression of pulmonary hypertension. These
results suggest that p38 mitogen-activated protein kinase might play a central role
in the molecular events that underlie the development and progression of pulmonary
hypertension.
CS
PPrimary pulmonary hypertension (PPH) is arapidly progressive disease without an identi-fiable cause characterized by a sustained in-crease in pulmonary artery pressure (PAP)and right heart failure. Occurring in approxi-mately 2 per million individuals, the persis-
tent and progressive nature of PPH ultimately leads to death,
with a median survival of 2.5 years.1 Secondary pulmonary
hypertension is associated with collagen vascular disease,
portal hypertension, congenital systemic-to-pulmonary
shunts, and HIV infection. PPH and secondary pulmonary
hypertension have been grouped by the World Health Or-
ganization (Evian, France, 1998) as group I (pulmonary
arterial hypertension) because of similar pulmonary his-
topathologic findings and responses to pharmacologic ther-
apy. The histopathologic features of PPH in small- and
medium-sized arterioles include endothelial cell prolifera-
tion with subsequent intimal fibrosis, smooth muscle cell
proliferation leading to medial hypertrophy, adventitial
thickening, perivascular inflammatory infiltrates, and in situ
thrombosis.2 In PPH monoclonal endothelial cell prolifera-
tion and smooth muscle cell migration produce obliterative
intimal lesions called plexiform lesions that characterize the
disease.3
The pathogenesis of PPH also includes an inflammatory
response. In addition to perivascular infiltration of macro-
phages and lymphocytes, increased expression of inflam-
matory mediators, such as interleukin (IL) 1, IL-6, and
platelet-derived growth factor A have been shown in pul-
monary hypertension (PH).4-6 Furthermore, tumor necrosis
factor (TNF) , IL-1, IL-6, and transforming growth factor
(TGF)  induce pulmonary vascular remodeling.7 These
findings suggest that inflammation plays a significant role in
the pathogenesis of PH. However, the molecular mecha-
nisms responsible for the inflammatory response and vas-
cular remodeling in PH remain largely undefined.
Proteins of the mitogen-activated protein kinase
(MAPK) family are activated in a variety of physiologic and
pathophysiologic states.8,9 MAPKs are activated by distinct
signaling pathway that induce MAPK activity in response toesults in increased
The Journal of Thoracitranscription of genes that subserve growth, differentiation,
and inflammation. p38 MAPK exists in 4 different isoforms
that have different cellular functions; p38 is most often
associated with inflammation.10 Of interest, in a rat model
of PH induced by chronic hypoxia, c-Jun NH2-terminal
kinase, extracellular signal–regulated kinase (JNK), and p38
MAPK have been demonstrated to be constitutively ex-
pressed in fibroblasts explanted from the pulmonary artery
(PA)11,12; however, MAPK activities in other experimental
forms of PH or in human PPH have not been reported. The
goal of our study is to examine p38 MAPK inhibition of
cytokine expression in a model of PH that includes an
inflammatory component. More importantly, we were able
to obtain a level of reproducibility in our results with the
monocrotaline (MCT)–induced PH model that likely ex-
ceeds the degree of precision we would have obtained with
the chronic hypoxia-induced model. We therefore evaluated
p38 MAPK activity and the effect of long-term inhibition of
p38 MAPK with FR167653,* a recently described specific
inhibitor of p38 MAPK,13 on PH in a rat model of PH
induced by MCT.
Materials and Methods
Animals and Experimental Design
Male Sprague-Dawley rats (Charles River Japan, Inc, Yokohama,
Japan), 6 to 8 weeks of age and weighing 250 to 300 g, were
divided into 4 groups: (1) the control group (daily 0.9% saline, 1
mL administered intramuscularly); (2) the FR group (daily
FR167653 [Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan], 2 mg
· kg1 · d1 in 1 mL of saline administered intramuscularly); (3)
the MCT group (daily 0.9% saline, 1 mL administered intramus-
cularly the day after a single MCT dose of 60 mg/kg in 1 mL of
saline administered subcutaneously); and (4) the MCTFR group
(daily FR167653, 2 mg · kg1 · d1, in 1 mL of saline adminis-
tered intramuscularly the day after a single MCT dose).
Body weight (BW) was measured on a weekly basis for 4
weeks. At each week of the study, rats were intubated and started
on mechanical ventilation after general anesthesia was achieved
with pentobarbital sodium (30 mg/kg administered intramuscu-
larly). After determining the PAP with a small needle cannulated*1-[7-(4-Fluorophenyl)-1,2,3,4-tetrahydro-8 (4-pyridyl) pyrazoro [5-1-
c][1,2,4].
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CSPinto the main PA, heart and lung blocks were quickly explanted.
The lung tissues were frozen in liquid N2 and maintained at80°C
before use for molecular analysis or distended and fixed by means
of perfusion through the tracheal tube with 10% formalin at 20 cm
H2O pressure for 48 hours for histopathologic observation. After
removing the atria, heart tissues were further dissected and sepa-
rated into the right ventricle (RV) and the left ventricle plus
septum (LVS), and the dissected tissues were weighed individ-
ually. The RV/(LVS) ratio by weight was determined.
To evaluate the effect of long-term treatment with FR167653,
we collected blood samples and measured the serum levels of
glutamic oxaloacetic transaminase, glutamic pyruvate transami-
nase, creatine phosphokinase, alkaline phosphatase, blood urea
nitrogen, and creatinine in a separate series of rats treated with
FR167653 daily (2 and 10 mg · kg1 · d1 administered intra-
muscularly) on a weekly basis for 18 weeks by means of enzyme-
linked immunosorbent assay. Histopathologic findings in the brain,
heart, lung, liver, and kidney were assessed in rats killed each
week.
All animals were maintained in accordance with the “Guide for
the Care and Use of Laboratory Animals” published by the Na-
tional Institutes of Health and also with the Guideline for Animal
Experiments in Mie University School of Medicine.
p38 MAPK Activity Assay
Whole-cell protein, extracted from frozen lung tissue with an
ice-cold lysis buffer (Cell Signaling Technology, Inc, Beverly,
Mass), was stored at 80°C until the time of assay. The p38
MAPK activity was measured with a p38 MAPK assay kit (Cell
Signaling Technology, Inc). In brief, a selective immunoprecipi-
tate of active (phosphorylated) p38 MAPK was obtained from
whole-cell protein by using immobilized phospho-p38 MAPK
(Thr180/Tyr182) monoclonal antibody. The resulting immunopre-
cipitate was then incubated with activating transcription factor
(ATF) 2 fusion protein and cold adenosine triphosphate (ATP);
this allows immunoprecipitated active p38 MAPK to phosphory-
late ATF-2. The results were expressed as the immunoreactivity of
phosphorylated ATF-2 (Thr71) detected with enhanced chemilu-
minescence and determined by means of densitometry (NIH Image
1.62). Results are expressed as fold activation over a control.
Quantitative Reverse Transcriptase–Polymerase Chain
Reaction
Total RNA was isolated from frozen lung tissues by means of the
guanidium thiocyanate-phenol-chloroform method and stored at
80°Cuntil the timeof theassay.Quantitative reverse transcriptase–
polymerase chain reaction measurement used the LightCycler Sys-
tem (Roche Diagnostics GmbH, Mannheim, Germany). Sense and
antisense primers for rat TNF-, IL-1, monocyte chemotactic
protein (MCP) 1, and glyceraldehyde-3-phosphate dehydrogenase
were synthesized by using published cDNA sequences.14-17
Amounts of TNF-, IL-1, and MCP-1 cDNA were expressed
relatively, being divided by the amount of cDNA for glyceralde-
hyde-3-phosphate dehydrogenase to correct for the varying effi-
ciency of cDNA synthesis.
852 The Journal of Thoracic and Cardiovascular Surgery ● DeceHistopathologic and Immunohistochemical Analysis
Morphometric analyses of PA were conducted exactly as previ-
ously described.18 For histopathologic observations in lung tissues,
particularly percentage of medial wall thickness (MWT) or per-
centage of muscularization of the PA, the sections from the mid-
portion of the formalin-fixed lung tissues were stained with hema-
toxylin-eosin and elastica van Gieson stains. All arteries with
external diameters of greater than 15 m were assessed at 400
magnification. The structural type of each artery was determined as
muscular (ie, with a complete medial coat of muscle), partially
muscular (ie, with only a crescent of muscle), or nonmuscular (ie,
no apparent muscle). The external diameter and medial thickness
(ie, the distance between the external and internal elastic laminae)
were noted for all muscular and partially muscular arteries, and the
percentage of MWT was calculated by using the following for-
mula: %MWT  2  Medial wall thickness/External diameter 
100.
For the immunohistochemical analysis of macrophages or lo-
calization of phosphorylated p38 MAPK, the sections were stained
with specific antibodies (macrophage: ED3, Bachem AG, Buben-
dorf, Switzerland; phospho-p38 MAPK: 28B10, Cell Signaling
Technology, Inc). The number of macrophages was determined by
counting immunostained cells in 3 sections per rat and 250 
250–m portions of 20 fields at 400 magnification per section.
Statistical Analysis
All data are expressed as means  SD. The significance of the
difference between group means was analyzed by means of 1-way
analysis of variance (ANOVA) with post hoc comparisons by
using the Fisher protected least-significant-difference test. The
effect of FR167653 was tested by means of 2-factor ANOVA for
repeated measures, and differences at specific time points between
the groups were assessed by means of 1-factor ANOVA with post
hoc comparisons by using the Fisher protected least-significant-
difference test. Relationships between 2 variables were tested by
using linear regression analysis. All statistical analyses were done
with StatView 6.0 (SAS Institute, Inc, Cary, NC).
Results
Hemodynamic Assessments and Right Ventricular
Hypertrophy
Over the course of the 4-week study period, rats treated with
MCT alone had retardation of growth (as measured on the
basis of percentage BW gain) compared with that of saline-
treated control animals (6.1%  5.1% vs 56.4%  4.4%,
P  .005). FR167653 administered daily over the 4-week
study period attenuated MCT-induced growth retardation;
MCTFR167653-treated animals gained just as much BW as
control rats treated with only saline (51.8% 8.8%; Figure 1, A).
Four weeks after MCT administration, the MCT-treated
rats exhibited significant PH with a mean PAP of 36.5 2.1
mm Hg, which is increased compared with that seen in
control animals (17.5 1.6 mm Hg, P .0001). FR167653
treatment attenuated the development of PH, reducing the
MCT-induced mean PAP increase to 24.7  1.9 mm Hg
(P  .001; Figure 1, B). Furthermore, the development of
mber 2004
ersus
Lu et al Cardiopulmonary Support and Physiology
CS
Pchronic PH resulted in a compensatory right ventricular
hypertrophy (RVH), as measured on the basis of an in-
creased RV/(LVS) ratio. MCT-treated rats had RVH with
a higher RV/(LVS) ratio when compared with values seen
in control animals (P  .05). FR167653 treatment reduced
RVH (P  .05; Figure 1, C).
The serum levels of glutamic oxaloacetic transaminase,
glutamic pyruvate transaminase, creatine phosphokinase,
alkaline phosphatase, blood urea nitrogen, and creatinine in
rats treated with FR167653 daily (2 and 10 mg · kg1 · d1
administered intramuscularly) for up to 18 weeks stayed
within normal limits. Also, we did not detect any abnormal
Figure 1. Effects of FR167653 on hemodynamic assess
ments of percentage BW gain (%BWG; A), mean PAP (
and MCTFR groups at 4 weeks after MCT or saline a
*P < .05 versus control group at 4 weeks; †P < .05 vfindings in histopathologic assessment of the brain, heart,
The Journal of Thoracilung, liver, and kidney (data not shown). Thus chronic
administration of FR167653 to rats has no apparent toxicity.
Morphometric Analysis of the PA
Representative sections, including small and large PAs from
all groups at 4 weeks after initial treatment with MCT, were
stained for elastin to reveal the inner elastic lamina (Figure
2, A). The percentage of MWT in the MCT-treated rats was
increased compared with that seen in the control rats (P 
.005). FR167653 treatment in the MCTFR group reduced
this increase in the percentage of MWT (P  .05; Figure 2,
B). The degree of medial hypertrophy in the MCT-treated
s in rats with MCT-induced PH. Shown are measure-
d RV/(LVS) ratio as RVH (C) in the control, FR, MCT,
istration. Values represent means  SD of 5 animals:
MCT group at 4 weeks.ment
B), an
dminanimals at the end of the 4-week period increased signifi-
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CSPcantly in PA segments at the alveolar wall and duct levels
(P  .05 vs control). FR167653 treatment reduced medial
hypertrophy at the alveolar wall level (P  .05), but there
was no effect on the midlayer at the alveolar duct level
Figure 2. Effects of FR167653 on morphometric analysis
logic findings of PAs with external diameters of less t
original magnification 400; A); measurements of perc
with external diameters of less than 50 m, 51 to 1
muscularized PA (% Muscularization) in normally non
wall levels (C) in the control, FR, MCT, and MCTFR gr
means  SD of 4 animals: *P < .05 versus period-m
MCT-treated animals.(Figure 2, C).
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p38 MAPK activity was increased at 1 week in the rats
treated with MCT alone (P  .005). Thereafter, the fold
increase of p38 MAPK activity in the MCT-treated group
in rats with MCT-induced PH. Shown are histopatho-
50 m and greater than 101 m (elastica van Gieson,
ge of medial wall thickness of muscular PA (%MWT)
m, and greater than 101 m (B); and percentage of
ular peripheral PA at the alveolar duct and alveolar
at 4 weeks after MCT administration. Values represent
ed control animals; †P < .05 versus period-matchedof PA
han
enta
00 
musc
oups
atchcompared with that in the control group remained increased
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Pbut decreased progressively over the 4 weeks of the study.
In the FR167653-treated group, however, p38 MAPK ac-
tivity was attenuated at 1, 2, and 3 weeks after MCT
treatment and completely blocked by 4 weeks (P  .05 vs
MCT; Figure 3).
Immunohistochemical analyses of lung tissue from
MCT-treated rats at 1 week after treatment demonstrated
increased phospho-p38 MAPK staining localized in the
endothelial and subendothelial layers of the PA. Phospho-
p38 MAPK also localized in alveolar macrophages sur-
rounding the intra-acinar PA and alveolar spaces. In con-
trast, FR167653 treatment reduced phospho-p38 MAPK
in MCT-treated rats to a level comparable with that in
lung tissue from control rats not treated with MCT (Fig-
ure 4).
Cytokine Expression in the Lung
TNF- mRNA expression increased at 1, 2, and 3 weeks
after MCT administration compared with that seen in age-
matched control animals (P  .005). By 4 weeks, TNF-
mRNA levels returned to baseline. FR167653 completely
inhibited TNF- mRNA expression at all time points after
Figure 3. Effects of FR167653 on p38 MAPK activity in t
analysis of phospho-ATF-2 expression after immunopr
MAPK activities denoted as fold activation over those o
 SD of 8 animals: *P < .01 versus period-matched co
animals.MCT treatment (P  .05 vs MCT; Figure 5, A). IL-1
The Journal of ThoracimRNA expression was also upregulated in rats treated with
MCT administration compared with that seen in age-
matched control animals (P  .005), and FR167653
blocked IL-1 mRNA expression (1 week, P  .005 vs
MCT; 2, 3, and 4 weeks, P  .05; Figure 5, B). Similar to
TNF- and IL-1, MCP-1 mRNA expression in the MCT
and MCTFR groups at 1 week after MCT administration
was greater than that seen in period-matched control rats
(P  .001). Thereafter, MCP-1 expression decreased to the
same levels as that of period-matched control rats.
FR167653 treatment had no effect on either the increase or
decrease in MCP-1 expression induced by MCT (Figure 5,
C).
Macrophage Infiltration in the Lung
The number of macrophages in the lung tissue, particularly
in the alveolar spaces and surrounding PA, increased in rats
treated with MCT and in MCT-treated rats also treated with
FR167653 compared with that seen in period-matched con-
trol animals (P  .01). FR167653 treatment showed a trend
toward decreased macrophage infiltration; however, this did
ngs of rats with MCT-induced PH: A, Western blotting
tation and kinase assay as p38 MAPK activity; B, p38
eriod-matched control animal. Values represent means
animals; †P < .05 versus period-matched MCT-treatedhe lu
ecipi
f a p
ntrolnot reach statistical significance (Figure 6).
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The pathogenesis of PH involves vasoconstriction, pulmo-
nary vascular remodeling, in situ thrombosis, and inflam-
mation. The inflammatory hypothesis of PH is supported by
multiple experimental studies demonstrating a perivascular
inflammatory cell infiltrate, abnormal TGF- signaling (in
both familial and sporadic PPH), increased expression of
adhesion molecules (vascular cell adhesion molecule 1,
intracellular adhesion molecule 1, and E-selectin), and up-
regulation of chemokines (eg, macrophage inflammatory
Figure 4. Immunohistochemical analyses for phospho-p
at 1 week after initial treatment (A; original magnificat
PAs in MCT-treated rats (original magnification 800).
intra-acinar PA in MCT-treated rats. PA, Pulmonary arprotein 1).4,6,8,19 In addition, inflammatory mediators,
856 The Journal of Thoracic and Cardiovascular Surgery ● Decesuch as TNF-, IL-1, IL-6, TGF-, vascular endothelial
growth factor, and platelet-derived growth factor, have been
shown to play a central role in pulmonary vascular remod-
eling.7 The role of inflammation in PH is further supported
by the clinical improvement observed in a subset of patients
with PH after steroid treatment or immunosuppressive ther-
apy.20,21 Multiple studies suggest that the initial inciting
event in the development of PH might be endothelial cell
injury by an unknown mechanism.22 Injured endothelium
can be activated to express adhesion molecules, vasoactive
APK localization (dark brown) in large and small PAs
00). High-power resolution in small (B) and large (C)
pho-p38 MAPK–positive macrophages surrounding the
Br, bronchiole.38 M
ion 4
Phossubstances (eg, endothelin), cytokines, chemokines, and
mber 2004
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Pgrowth factors.23 The subsequent inflammatory and proco-
agulant responses are thought to promote smooth muscle
cell proliferation, vasoconstriction, and in situ thrombosis,
resulting in pulmonary vascular remodeling and PH and
ultimately right heart failure. To clarify the molecular mech-
anism underlying the development and progression of in-
flammation in PH, we examined p38 MAPK activation and
inflammatory cytokine expression in MCT-induced PH in
rats. p38 MAPK activity is associated with inflammation in
a variety of systems, and we believe MCT-induced PH and
many forms of human PH are, in part, inflammatory con-
ditions. In addition, p38 MAPK is involved in the vessel
wall response to mechanical stress, which might also con-
tribute to PH in a subgroup of causes.24
MCT-induced PH in rats and human PH are similar in
Figure 5. Effects of FR167653 on quantitative reverse t
(A), IL-1 (B), and MCP-1 (C) mRNA in the lungs of ra
increase over values in period-matched control ani
normalized to that of glyceraldehyde-3-phosphate dehy
of 8 animals: *P < .05 versus period-matched contro
animals.the following respects. First, early pathologic changes in-
The Journal of Thoraciclude PA endothelial swelling and blebbing and alveolar
inflammatory infiltrates similar to those seen in clinical PH.
Later changes include progressive vascular remodeling
characterized in part by increased elastin and collagen pro-
tein synthesis and deposition. Second, histologically, both
show medial hypertrophy involving the PAs. Third, tro-
poelastin and type I collagen staining are positive in both.
Fourth, cytokine expression occurs in both and might be
causally related in both. Finally, neointimal formation in
response to injury occurs in both, although to a more pro-
nounced degree in human PH.25,26 However, so-called plex-
iform lesions, which are present in human PH, are not
detected consistently in MCT-induced PH in rats.27 MCT is
a pyrrolizidine alkaloid that induces pulmonary vascular
injury. Infiltration of mononuclear cells, particularly mac-
riptase–polymerase chain reaction analysis of TNF-
ith MCT-induced PH. The vertical axis denotes a fold
after the amount of mRNA for each cytokine was
enase (GAPDH) mRNA. Values represent means  SD
imals; †P < .05 versus period-matched MCT-treatedransc
ts w
mals
drog
l anrophages, is a prominent pathologic feature of MCT-in-
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CSPduced PH in the early phase.28 Recent studies suggest that
inflammatory cytokines, such as IL-1 and IL-6, which are
produced by infiltrating macrophages, play a role in not only
MCT-induced PH in rats7,29 but also a variety of human
diseases, including PPH.4 Also, MCP-1 expression is asso-
ciated with the development of MCT-induced PH in
rats.30,31
We initially included TNF- assays as a negative control
because of a report showing normal circulating serum levels
of TNF- in patients admitted with PH for lung transplan-
tation.5 We were therefore surprised by increased levels of
TNF- mRNA in lung tissue in MCT-treated rats. It is quite
possible that TNF- released from resident mononuclear
phagocytes is released and acts locally and would not be
detected systemically. It is also possible that TNF- tran-
scription is upregulated in PH, but translation of TNF-
mRNA does not occur. These issues deserve further study.
Furthermore, we are aware that although TNF- induces
p38 MAPK activity, p38 MAPK might signal TNF- ex-
pression.32
p38 MAPK activation is involved in a variety of cellular
responses, including inflammatory cytokine production, cell
growth, cellular differentiation, and apoptosis.33 p38 MAPK
activation is induced in vascular smooth muscle cells and
endothelial cells by means of atherogenic stimuli, such as
mechanical stress, TNF-, IL-1, or oxidative stress.34
Moreover, p38 MAPK is activated by chronic hypoxic
stress, causing proliferation of the PA fibroblasts required
for remodeling of the pulmonary vasculature in hypoxia-
induced PH.11,12 In this study we find an increase in
p38MAPK activity in MCT-treated rat lungs, and we dem-
onstrate that the production and action of many of the
potential inflammatory mediators of PPH are associated
Figure 6. Effects of FR167653 on numbers of interstitial macro-
phages in the lungs of rats with MCT-induced PH. Values repre-
sent means  SD of 8 animals: *P < .05 versus period-matched
control animals.with activation of the p38 MAPK signaling pathway.33
858 The Journal of Thoracic and Cardiovascular Surgery ● DeceOther signaling pathways, however, acting in concert with
p38 MAPK activation might also be involved in the devel-
opment of PH.35The use of specific p38 MAPK inhibitors
for the treatment of inflammatory diseases has recently been
examined.36 In this study we have demonstrated that
FR167653, a selective p38 MAPK inhibitor, decreased the
expression of TNF- and IL-1 in the PA and also pre-
vented progression of PH in MCT-induced rats with PH.
Although the expression of TNF- mRNA appeared to be
disassociated from p38 MAPK activity, likely this was due
to the time needed for transcription and translocation of
TNF- after these events were initiated by the p38 MAPK
pathway. The attenuation of inflammatory-mediated PH by
FR167653 occurred without a decrease in expression of
MCP-1, a potent chemotactic factor for macrophages, or in
the number of interstitial macrophages migrating into the
vessel wall. We therefore infer that MCP-1 secretion from
activated human mononuclear phagocytes in PH is not
dependent on p38 MAPK activity.37
MCT is converted in the liver by cytochrome P450
mono-oxygenases to monocrotaline pyrrole (MCTP) and
other pyrrolic metabolites, which then travel to the pulmo-
nary circulation. The chemical nature of MCTP suggests
that it is an important pneumotoxic metabolite because
MCTP is among the more stable toxic primary pyrrolizidine
alkaloid pyrroles. MCTP binds to tissue components and
initiates toxicity, beginning within the first 24 hours of
MCT treatment in rats.38,39 Therefore FR167653 treatment
beginning the day after MCT administration in our model
does not effect the bioactivation of MCT.
Most previous studies that have examined the roles of
p38 MAPK in cellular function have used SB203580 to
inhibit p38 MAPK. SB203580 activity is not confined to
inhibition of p38 MAPK. SB203580 has also been reported
to inhibit thromboxane synthase,40 COX-1 and -2,40 and
JNKs.41 This nonspecific action of SB203580 might explain
contradictory mechanistic conclusions regarding the role of
p38 MAPK. FR167653 is specific for p38 MAPK inhibitor,
with no measurable affect on COXs or other MAPKs.13
We thank Dr Kazuo Maruyama (Professor, Department of
Anesthesiology, Mie University School of Medicine) for the tech-
nical advice of producing PH model in rats and Dr Taizo Shiraishi
(Professor, the Second Department of Pathology, Mie University
School of Medicine) for histopathologic advice, as well as Fuji-
sawa Pharmaceutical Co, Ltd. for their generous gift of FR167653.
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